ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
BeOne Medicines Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$370.17+1.11 (+0.30%)
Close on Oct 19, 2026
- Market cap
- $557.24B
- P/E (TTM)
- 860.9
- Dividend yield
- –
BeOne Medicines Ltd. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $1.68B | $1.49B | $1.48B | $1.40B | $1.30B | $1.11B | $1.12B | $993.45M | $921.15M | $746.92M | $630.53M | $595.29M | 98.5% | +29.0% |
| BRUKINSA | $1.25B | – | – | – | $949.84M | – | – | – | – | – | – | – | 73.2% | +31.4% |
| TEVIMBRA | $228.52M | – | – | – | $193.52M | – | – | – | – | – | – | – | 13.4% | +18.1% |
| XGEVA | $104.50M | – | – | – | $81.32M | – | – | – | – | – | – | – | 6.1% | +28.5% |
| Other | $37.82M | – | – | – | $21.15M | – | – | – | – | – | – | – | 2.2% | +78.8% |
| BLINCYTO | $36.54M | – | – | – | $25.59M | – | – | – | – | – | – | – | 2.1% | +42.8% |
| Other Revenue | $25.28M | $26.11M | – | $17.27M | $13.22M | $8.75M | – | $8.15M | – | – | – | – | 1.5% | +91.1% |
| KYPROLIS | $15.15M | – | – | – | $19.42M | – | – | – | – | – | – | – | 0.9% | -22.0% |
| POBEVCY | $9.63M | – | – | – | $11.24M | – | – | – | – | – | – | – | 0.6% | -14.3% |
| Other revenue | – | – | – | – | $13.22M | $8.75M | $9.79M | $8.15M | $8.02M | $4.73M | $3.88M | $186.02M | – | – |
| Research and development service revenue | – | – | – | – | – | – | – | – | – | – | – | $59.05M | – | – |
| Other | – | – | – | – | – | – | – | – | – | – | – | $3.01M | – | – |
| Right to access intellectual property revenue | – | – | – | – | – | – | – | – | – | – | – | $51.98M | – | – |
| Tislelizumab | – | – | – | – | – | – | – | – | – | – | – | $54.00K | – | – |
| Material rights revenue | – | – | – | – | – | – | – | – | – | – | – | $71.98M | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $914.21M | $782.26M | $863.83M | $754.86M | $694.43M | $567.21M | $619.15M | $505.46M | $481.43M | $351.46M | $313.16M | $398.23M | 53.6% | +31.6% |
| China | $506.02M | $471.97M | $407.13M | $439.89M | $432.92M | $399.59M | $362.87M | $375.99M | $352.07M | $320.38M | $270.55M | $287.94M | 29.7% | +16.9% |
| Europe - total revenue | $208.76M | $194.00M | $173.86M | $166.58M | $152.38M | $118.55M | $115.11M | $98.27M | $82.39M | $66.86M | $48.74M | $85.58M | 12.2% | +37.0% |
| Rest of world - total revenue | $76.09M | $65.21M | – | $50.97M | $35.57M | $31.92M | $30.69M | $21.88M | $13.28M | $12.96M | $1.96M | $9.56M | 4.5% | +113.9% |
From the segment and revenue-disaggregation notes of BeOne Medicines's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.